[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Artivion Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100599829","clinical-study-to-evaluate-the-safety-and-effectiveness-of-arcevo-lsa-100599829",false,"NCT07089576","Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA","A Prospective, Multi-center Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA in the Open Repair of Aortic Arch Aneurysms and Dissections","ARTIZEN","General Inclusion Criteria\n\n1. ≥18 years of age or ≤80 years of age (male or female) at time of surgery\n2. Patient has one of the following indications for open surgery based on computed tomography angiography (CTA) completed within 90 days of informed consent:\n\n   * Acute, subacute, or chronic dissection that involves the aortic arch and the descending thoracic aorta, with or without involvement of the ascending aorta\n   * Aneurysm that involves the aortic arch and the descending thoracic aorta, with or without involvement of the ascending aorta\n3. Patient, or patient's legally authorized representative (LAR; in the secondary arm only), provides written informed consent prior to any study procedures\n4. Patient's surgery occurs within 90 days of informed consent\n\n   Anatomical Inclusion Criteria\n5. Aortic diameter at the intended Arcevo™ LSA anastomosis site is ≥ 21 mm\n6. For Aneurysm with distal sealing (i.e., single stage procedure), aortic diameter at the intended distal sealing zone is between 20-36 mm\n7. For Dissection with distal sealing, aortic diameter at the intended distal sealing zone is between 22-40 mm\n8. LSA branch does not require additional stenting further into the LSA (beyond the Arcevo™ LSA)\n9. The intended LSA sealing zone has a diameter between 8.5 mm and 14.0 mm with a length of at least 10 mm\n10. Absence of dissection, aneurysm, or stenosis in the intended LSA sealing zone\n11. The intended LSA branch position does not interrupt flow to any branch vessel (e.g., left vertebral artery)\n12. Patient does not have computed tomography (CT) evidence of extreme arch or LSA angulation precluding safe passage of the Arcevo™ LSA and delivery system\n13. LSA take-off angle between 15° and 90°\n14. For patients requiring planned extension, there is a ≥ 2 cm distal seal zone for the TEVAR device without a severely angulated descending aorta\n15. For patients requiring planned extension, patient has suitable iliac artery anatomy for safe passage of the TEVAR delivery system\n\nGeneral Exclusion Criteria\n\n1. Patient is pregnant, or planning to become pregnant during the course of the study; individuals of child-bearing potential must agree to use acceptable methods of contraception during the study\n2. Patient has another medical condition (aside from the arch disease) that, in the opinion of the investigator, reduces the patient's life expectancy to \\\u003C 2 years\n3. Patient has an existing aortic stent graft device in the descending aorta that would interact with Arcevo™ LSA\n4. Patient has a medical, social, or psychological problem that, in the opinion of the investigator, could impede the patient's ability to return for follow-up\n5. Patient is unwilling or unable to comply with the follow-up schedule\n6. Patient is institutionalized due to administrative or judicial order\n7. Patient is unwilling to accept blood transfusion or blood product\n8. Patient is currently participating in another interventional clinical study which includes treatment with another investigational product (e.g., device, pharmaceutical or biologic)\n\n   Medical Exclusion Criteria\n9. Patient is unfit for open surgical repair involving circulatory arrest\n10. Patient is in extreme hemodynamic compromise requiring cardiopulmonary resuscitation (CPR) or substantial inotropic support prior to surgery\n11. Patient has an active systemic infection\n12. Patient has endocarditis or active infection of the aorta\n13. Patient has a freely ruptured aorta\n14. Patient has a history of a bleeding disorder (e.g., hemophilia)\n15. Patient has current end-stage renal disease (e.g., GFR \\\u003C30 mL\u002Fmin)\n16. Patient has a known allergy to Arcevo™ LSA components and TEVAR device components (if required) (nitinol, polyester, platinum-iridium, or polyethylene)\n17. Patient has uncontrollable anaphylaxis to iodinated contrast or other inability to obtain CT angiograms during follow-up\n18. Patient has acute coronary malperfusion\n19. Patient has symptomatic visceral malperfusion","ALL","18 Years","80 Years",{"count":21,"type":22},132,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and\u002For aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.",[28,29,30,31],"Aortic Arch Aneurysm","Aortic Arch Dissection","Chronic Aortic Dissection","Acute Aortic Dissection",[33,34,35,36],"total arch replacement","frozen elephant trunk","aortic arch aneurysm","aortic arch dissection","RECRUITING","2026-05-19",{"date":40,"type":41},"2026-05-22","ACTUAL",{"date":43,"type":41},"2025-11-04",{"date":45,"type":22},"2032-07",{"name":47,"class":48},"Artivion Inc.","INDUSTRY",19,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100624768","mitral-valve-repair-with-the-chord-x-system-a-long-term-evaluation-100624768","NCT07413926","Mitral Valve Repair With the Chord-X System: A Long Term Evaluation","METRIX","Inclusion Criteria:\n\n* Patient provided written Informed Consent\n* Patient underwent mitral valve procedure (defined as mitral valve surgical intervention via endoscopic, mini thoracotomy, or full sternotomy approach, including mitral annuloplasty with a ring, resection of mitral valve leaflets, and replacement of mitral chordae tendineae) using the Chord-X System as clinically indicated (i.e. not off-label) by Principal Investigator at research site\n* Patient's Chord-X System implant occurred no earlier than January 1, 2022\n* Patient is able and willing to participate in follow-up visits for the duration of the study (i.e. through 10 years post-op)\n\nExclusion Criteria:\n\n* Patient was implanted with the Chord-X System off-label\n* Patient was implanted with the Chord-X System prior to January 1, 2022\n* Patient has had previous mitral valve surgery\n* Patient underwent a multi valve repair procedure\n* Patient with an ejection fraction ≤ 50% at baseline\n* Patient underwent concomitant surgical procedures (except for maze procedure, PFO or LAA closure) at time of mitral repair procedure\n* Patient whose mitral valve procedure was performed as part of an emergency surgery (defined as a time period from diagnosis to surgery of ≤ 48 hours)\n* Patient with persistent or permanent atrial fibrillation\n* Patient with active or a history of endocarditis\n* Patient with congenital heart disease",{"count":58,"type":22},110,"10 Years","OBSERVATIONAL","The goal of this clinical trial is to strengthen the evidence available for the Chord-X System by collecting follow-up data from patients who underwent Chord-X implant and to evaluate the long-term safety and performance data (out to 10 years). Collecting patient health information over time can help to supplement and improve the care of patients in the future.\n\nParticipants will:\n\nAgree to the collection of their past medical history, and the details of their mitral repair surgery with the Chord-X system, including results of the follow-up examinations after implantation Visit the clinic for the routinely scheduled follow-up examination appointments",[63],"Mitral Regurgitation (MR)",[65,66],"mitral regurgitation","Chord-X","NOT_YET_RECRUITING","2026-02-18",{"date":70,"type":41},"2026-02-20",{"date":72,"type":22},"2026-06",{"date":74,"type":22},"2034-06",{"name":47,"class":48},4,""]